Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924527 | 0.93 | HSD17B10 (0.49) | HSD17B10GAAHCAR3TP53TSHR | |
| SCHEMBL924129 | 0.91 | HSD17B10 (0.51) | HSD17B10GAAHCAR3EPHX2KDM4E | |
| SCHEMBL21063571 | 0.84 | CHRNB2 (0.37) | HSD17B10GAATP53TSHRCA12 | |
| SCHEMBL14406963 | 0.84 | TP53 (0.35) | HSD17B10GAATP53TSHRPDK1 | |
| SCHEMBL21098659 | 0.83 | KMT2A (0.36) | GAATP53TSHRPDK1PDK2 | |
| SCHEMBL924794 | 0.81 | USP2 (0.40) | HSD17B10GAAHCAR3PDK1PDK2 | |
| SCHEMBL6206941 | 0.80 | ALDH1A1 (0.48) | HSD17B10GAATSHRPDK1PDK2 | |
| SCHEMBL19585639 | 0.75 | CRBN (0.51) | TSHRDDB1CRBNALDH1A1 | |
| SCHEMBL20812749 | 0.74 | DDB1 (0.35) | CA12CA1CA9USP2CA2 | |
| SCHEMBL924151 | 0.74 | ALDH1A1 (0.52) | HSD17B10GAATSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | claimed |
| CN-1684954-A | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2005-10-19 | — | — | CN | claimed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | claimed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | claimed |
| WO-2024046221-A1 | EGFR INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |
| CN-113264945-B | Spiro derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
| EP-1546133-B1 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2010-03-17 | — | — | EP | disclosed |
| CN-100528864-C | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2009-08-19 | — | — | CN | disclosed |
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| CN-1684954-A | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546133-A2 | N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6869966-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | NPY1R, NPY2R, NPY4R | HSD17B10 409/4885GAA 1984/4885HCAR3 82/4885 |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | GPR119, NPY4R, NPY1R | HSD17B10 718/4885GAA 1691/4885HCAR3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.